Impact of Gender on the Prognosis of Patients with Hepatocellular Carcinoma After Palliative Therapy
Objectives: Sex differences are ascribed to the risk of hepatocellular carcinoma (HCC); however, whether gender disparity also exists in the prognosis of palliative therapy is yet unclear. A retrospective cohort study was performed to assess the prognostic predictors after palliative therapy of HCC, focusing on sex differences.
Methods: This retrospective cohort study consisted of 2356 patients (270 women and 2086 men) with a diagnosis of HCC between 2006 and 2011. The patients received palliative care. Clinical and laboratory data were evaluated and compared.
Results: Overall, the two groups did not have significant sex-related differences in prognosis for overall survival (OS) of palliative care, including transarterial chemoembolization (TACE), chemotherapy, and best supportive care (BSC). Using multivariate analysis, the following were identified as independent risk factors of survival (P<0.05): smoking, liver cirrhosis, vascular invasions, tumor size, absolute value of neutrophils, and glutamyltransferase. Transarterial chemoembolization was regarded as protective factor of OS.
Conclusion: No significant differences were observed in the prognosis of male or female HCC patients after palliative care. The gender factor was not an independent predictor for OS.
1.Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. [CrossRef]
2. Villa E, Baldini GM, Pasquinelli C, Melegari M, Cariani E, Di Chirico G, ET AL. Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol. Cancer 1988;62:611–5. [CrossRef]
3. Evert M, Dombrowski F. Hepatocellular carcinoma in the noncirrhotic liver. Pathologe 2008;29:47–52. [CrossRef]
4. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993;67:635–7. [CrossRef]
5. Zhu RX, Seto WK, Lai CL, Yuen MF. epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016;10:332–9. [CrossRef]
6. Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994;74:2442–8. [CrossRef]
7. Ganne-Carrie N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, et al; for CIRRAL Group. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol 2018;69:1274–83. [CrossRef]
8. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000;60:5106–10.
9. Groupe d'Etude et de Traitement du Carcinome H. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004;40:1361–9. [CrossRef]
10. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121–4.
11. Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a genderspecific risk factor for liver cancer? Hepatology. 2007;46:1304– 5. [CrossRef]
12. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 2017;6:325–36. [CrossRef]
13. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014;146:1691–700. [CrossRef]
14. Piscaglia F, Ogasawara S. Patient Selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer 2018;7:104–19.
15. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Muller C, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261–73. [CrossRef]
16. Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24:2565–70. [CrossRef]
17. Xu L, Peng ZW, Chen MS, Shi M, Zhang YJ, Guo RP, et al. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol 2015;63:122–30. [CrossRef]
18. Wands J. Hepatocellular carcinoma and sex. N Engl J Med 2007;357:1974–6. [CrossRef]
19. Ladenheim MR, Kim NG, Nguyen P, Le A, Stefanick ML, Garcia G, et al. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterol 2016;3:e000107.
20. Buch SC, Kondragunta V, Branch RA, Carr BI. Gender-based outcomes differences in unresectable hepatocellular carcinoma. Hepatol Int 2008;2:95–101. [CrossRef]
21. Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:267–72.
22. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–73.
23. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899– 919.
24. Ruggieri A, Gagliardi MC, Anticoli S. Sex-dependent outcome of Hepatitis B and C viruses infections: synergy of sex hormones and immune responses?. Front Immunol 2018;9:2302.
25. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009;50:1392–402. [CrossRef]